Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
22.08.2024 14:17:01
|
Health Canada Approves Keytruda-Padcev Combo For Certain Patients With Urothelial Cancer
(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication.
Keytruda in combination with antibody-drug conjugate Padcev (enfortumab vedotin) has been approved for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
The approval was based on results from the phase III KEYNOTE-A39 trial, in which the combination of KEYTRUDA and enfortumab vedotin demonstrated statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy.
Keytruda received its first approval in Canada in 2015. The drug is approved for a number of indications including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma.
In pre-market activity on the NYSE, the shares are trading at $116.20, up 0.15%.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
01.04.25 |
Schwacher Handel in New York: Dow Jones präsentiert sich schwächer (finanzen.at) | |
01.04.25 |
Freundlicher Handel in New York: Dow Jones am Dienstagmittag mit Zuschlägen (finanzen.at) | |
01.04.25 |
Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Gewinn hätte ein Investment in Merck von vor 5 Jahren eingefahren (finanzen.at) | |
01.04.25 |
Minuszeichen in New York: Dow Jones zum Handelsstart in Rot (finanzen.at) | |
28.03.25 |
Verluste in New York: Dow Jones präsentiert sich schlussendlich leichter (finanzen.at) | |
28.03.25 |
Minuszeichen in New York: S&P 500 sackt nachmittags ab (finanzen.at) | |
28.03.25 |
Börse New York: Dow Jones verbucht am Freitagnachmittag Verluste (finanzen.at) | |
28.03.25 |
Schwacher Handel: Dow Jones am Freitagmittag schwächer (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 80,60 | -2,54% |
|